Prostate%20cancer Signs and Symptoms

Signs and Symptoms

Introduction

Second most common cancer in men; one of the most common cancers in men >50 years of age

Signs and Symptoms

Weak urinary stream, incomplete bladder emptying
Polyuria, nocturia
Hematuria
Erectile dysfunction
Pelvic pain, back pain, chest pain
Lower extremity weakness or numbness
Loss of bladder or bowel control

Risk Factors

Age (increased risk in men >50 years old)
Positive family history: First- or second-degree relatives diagnosed with metastatic prostate, ovarian, breast (female ≤45 years old), colorectal, endometrial (≤50 years old) or pancreatic cancer, and those with ≥2 first- or second-degree relatives diagnosed with prostate, breast, colorectal or endometrial cancer at any age
Ethnicity (African ancestry, Ashkenazi Jewish descent)
Chemical exposures (toxic combustion products)
Genetic mutations: Breast cancer susceptibility gene 1 (BRCA1), breast cancer susceptibility gene 2 (BRCA2), ataxia telangiectasia mutated (ATM), checkpoint kinase 2 (CHEK2), homeobox B13 (HOXB13), epithelial cellular adhesion molecule (EPCAM), nibrin (NBN), tumor protein 53 (TP53), partner and localizer of BRCA2 (PALB2), deoxyribonucleicacid (DNA) mismatch repair genes (mutS homolog 2 [MSH2], mutL homolog 1 [MLH1], Lynch syndrome, mutS homolog 6 [MSH6], post-meiotic segregation increased 2 [PMS2]), insulin-like growth factor-1 (IGF-1)
Other risk factors under research include a positive medical history of inflammation of the prostate gland (eg prostatitis, sexually transmitted diseases [STDs], proliferative inflammatory atrophy [PIA]) and vasectomy

Tumour-treating fields – a versatile treatment modality for multiple cancer types

Dr. Uri Weinberg, Dr. David Tran, Prof. Thomas Seufferlein, 13 Dec 2021

Tumour-treating fields (TTFields) are a noninvasive cancer treatment modality, which first demonstrated clinical benefits in combination with chemotherapy in glioblastoma multiforme (GBM). At a webinar organized by the Hong Kong Cancer Therapy Society (HKCTS), experts discussed TTFields’ potential in other cancer types, including hepatocellular carcinoma (HCC) and pancreatic cancer, and the rationale for combining TTFields with immunotherapy.

Adding an androgen-receptor inhibitor to docetaxel and ADT in patients with mHSPC

Dr. Adrian Tse, 13 Dec 2023

A 68-year-old male patient presented with bone pain at multiple sites in November 2022. He did not have any other symptoms. He had hypertension and type 2 diabetes mellitus (T2DM), which were well controlled with amlodipine besylate 5 mg BID and metformin 1 g BID, respectively. He was generally well and had a baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0.

Use of a novel erythroid maturation agent in transfusion-dependent β-thalassaemia

Dr. Gloria Yu-Yan Hwang, 28 Apr 2023

A 45-year-old female, diagnosed in infancy with transfusion-dependent β-thalassaemia (TDT) major of β⁰/β⁰genotype, presented with a liver abscess in December 2019. She was admitted to hospital multiple times for repeated drainage of the abscess, which was caused by Klebsiella, and required several prolonged courses of antibiotic treatment. The patient was on a regular transfusion schedule of 3 red blood cell (RBC) units every 4 weeks in addition to iron chelator therapy with intravenous (IV) deferoxamine and oral deferasirox.